Clinical Trials
196 trialsNCT07146919 2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2 Withdrawn
NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
NCT07211204 2026-03-03
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
Timser SAPI de CV
Phase NA Withdrawn
NCT05512260 2026-02-11
BESTa
Karolinska Institutet
Phase NA Withdrawn
NCT07226102 2026-02-04
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
City of Hope Medical Center
Phase NA Withdrawn
NCT05850663 2026-02-03
Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer
University of Oklahoma
Phase NA Withdrawn
NCT02554344 2026-01-30
Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)
Baylor Research Institute
Phase EARLY_PHASE1 Withdrawn
NCT06545617 2026-01-07
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
Phase 1/2 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06866951 2025-12-16
A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial
Women's Hospital School Of Medicine Zhejiang University
Phase 2/3 Withdrawn
NCT05483023 2025-10-14
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT02446652 2025-05-29
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
Phase 3 Withdrawn
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT02756130 2025-05-13
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
NCT06385548 2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2 Withdrawn
NCT05714306 2025-03-05
CHUV-OVACURE
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Withdrawn
NCT03197584 2025-02-21
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03632798 2025-02-12
ACSCO
Cordgenics, LLC
Phase 3 Withdrawn
NCT06120972 2025-02-12
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
University of Pittsburgh
Phase 2 Withdrawn
NCT06681870 2025-01-15
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT05145569 2025-01-01
Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT05289648 2024-12-19
NIREC
Sir Mortimer B. Davis - Jewish General Hospital
Phase EARLY_PHASE1 Withdrawn
NCT03238053 2024-10-16
Laser Treatment of Genito-urinary Syndrome in Women
Herning Hospital
Phase NA Withdrawn
NCT06161493 2024-10-15
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
University of Pittsburgh
Phase 1 Withdrawn
NCT05826015 2024-10-02
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
Phase 1 Withdrawn
NCT06099418 2024-09-20
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
Nykode Therapeutics ASA
Phase 2 Withdrawn
NCT05655598 2024-09-19
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Brown University
Phase 1 Withdrawn
NCT06216561 2024-08-20
Intraperitoneal LSTA1 in CRS-HIPEC
University of California, San Diego
Phase 1 Withdrawn
NCT03150745 2024-07-31
Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix
Assiut University
Phase NA Withdrawn
NCT06046274 2024-04-30
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
Genmab
Phase 2 Withdrawn
NCT04542603 2024-04-25
Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT06284226 2024-04-16
CCT-ANK-11
Beijing Kejing Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Withdrawn
NCT05390021 2024-04-02
PET/MRI in Endometrial Cancer
Massachusetts General Hospital
Phase NA Withdrawn
NCT05033132 2024-03-28
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Agenus Inc.
Phase 2 Withdrawn
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05465590 2023-12-21
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Mainline Biosciences, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT03735589 2023-11-22
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT05998941 2023-11-22
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Withdrawn
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT05905341 2023-11-08
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT05712941 2023-11-03
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
EQRx International, Inc.
Phase 3 Withdrawn
NCT05295589 2023-09-26
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05201001 2023-09-11
APX005M
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT01225757 2023-08-14
Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC
University of Nebraska
Phase NA Withdrawn
NCT00298064 2023-07-05
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
University of New Mexico
Phase NA Withdrawn
NCT05614453 2023-06-29
ITTACC
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn